Recent Updates
Recently added Catalysts

EVO101

Phase 2

Atopic Dermatitis Eczema | Small molecule | Dermatology |Evommune, Inc.|Last Updated: Mar 5, 2025

Success Probability
Subscribe to view
Market & Valuation
Subscribe to view
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment119
FDA Designations
No designations recorded
Clinical trial landscape

EVO101 · 2 trials · 2 indications

Phase 2 1Early Phase 1 1
NCT05579899Safety and Efficacy Study of EVO101 Topical Cream in Atopic DermatitisAtopic Dermatitis Eczema
COMPLETED119 Analytics
PHASE2COMPLETED
Safety and Efficacy Study of EVO101 Topical Cream in Atopic Dermatitis
Atopic Dermatitis Eczema
NCT05579899119
Unlock trial analytics
Study Endpoints
Primary Endpoints
Percent Change in Eczema Area and Severity Index (EASI) From Baseline to Week 8
8 weeks

EASI assesses the extent and severity of atopic dermatitis. EASI is a composite index with scores ranging from 0 to 72. Higher values indicate more severe or extensive disease.

The efficacy of EVO101 on hidradenitis suppurativa will be evaluated using two parameters: decrease in lesion count and change in patient reported outcomes (PRO)
12 Weeks

The change in the total HS lesion count will be assessed at Week 4, Week 8, and Week 12. The percent change from Baseline will be calculated.

Secondary Endpoints
Investigator Global Assessment (IGA) Response (Number of Participants With >= 2 Points Change From Baseline to Week 8)
8 weeks
Percent Body Surface Area (BSA) Affected by Atopic Dermatitis Over Time, Change From Baseline to Week 8
8 weeks
Pruritus-NRS, Change From Baseline to Week 8
8 weeks
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingTRIPLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
EVO101 CreamEXPERIMENTALActive Treatment, BID, 8 weeks
Vehicle CreamPLACEBO_COMPARATORVehicle Treatment, BID, 8 weeks
Open label EVO101 topical cream 0.1%EXPERIMENTALAll eligible subjects will receive open label EVO101 topical cream 0.1%
Interventions
NameTypeDescription
EVO101DRUGTopical Cream
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites21

Inclusion Criteria: 1. Males or non-pregnant, non-lactating females, age 18 years or older 2. Chronic atopic dermatitis for at least 1 year 3. IGA score of 2 or 3 4. BSA of AD involvement of 4-12% 5. EASI of 5-20 Exclusion Criteria: 1. Significant AD flare with 4 weeks 2. Use of biologic therapy ...

Countries:United States
Unlock Eligibility Criteria
Recent Changes (Last 90 Days)
LOWMay 26, 2026NCT06645821primaryCompletionDate: changed
LOWMay 24, 2026NCT06645821studyFirstPostDate: changed